Evidence map›Paper›PMID 21720831›Full record

ArticleDer Urologe. Ausg. A2011

[Overweight is an advantageous prognostic marker in patients with clear cell kidney cancer].

S Waalkes, H Eggers, J Rustemeier, G Wegener, F Jentzmik, M Schrader, R Hofmann, M A Kuczyk, A J Schrader, Für das deutsche Netzwerk Nierenzelltumoren

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Der Urologe. Ausg. A, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

S WaalkesKlinik für Urologie und urologische Onkologie, Medizinische Hochschule Hannover, Hannover, Deutschland.
H Eggers
J Rustemeier
G Wegener
F Jentzmik
M Schrader
R Hofmann
M A Kuczyk
A J Schrader
Für das deutsche Netzwerk Nierenzelltumoren
Medizinische Hochschule Hannover · DEKlinik und Poliklinik für Urologie · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesObesity increases the risk of developing renal cell carcinoma (RCC). We assessed whether different body mass index (BMI) levels and the body surface area (BSA) at the time of surgery had an effect on aggressiveness and long-term prognosis of RCC.

methodsThe study included 1,595 RCC patients with complete information about their BMI who had undergone surgery for renal cell cancer at the University Hospitals in Hannover (MHH) and Marburg between 1990 and 2005. The mean follow-up was 5.0 years.

resultsA higher BMI and a higher than average BSA were significantly associated with younger age. A high BMI value was additionally related to a lower tumor grade, the clear cell histological subtype, and metastasis at the time of diagnosis. Overweight patients had a significantly lower risk of cancer-related death; their median 5-year tumor-specific survival rate was 76.9% (BMI>30) and 72.6% (BMI 25-30) as opposed to 63.5% for patients with a BMI below 25 (p<0.001). However, the positive correlation between a high BMI and tumor-specific survival could be confirmed in multivariable analyses for localized clear cell RCC only.

conclusionWe identified BMI as an independent prognostic marker of improved cancer-specific survival in patients with RCC, particularly with organ-confined clear cell cancer.

Indexed as

Body Mass IndexAbdominal NeoplasmsAdultAgedAged, 80 and overBody Surface AreaCarcinoma, Renal CellComorbidityFemaleGermanyHumansKidney NeoplasmsLung NeoplasmsMaleMiddle AgedNeoplasm Staging

Identifiers

PMID21720831
OpenAlexW25033765

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.